開立醫療(300633.SZ)2021年度預盈2.05億-2.55億元 同比扭虧為盈
格隆匯1月21日丨開立醫療(300633.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤2.05億元-2.55億元,上年同期為虧損4626.31萬元;扣除非經常性損益後的淨利潤1.72億元-2.22億元,上年同期為虧損9034.22萬元。業績變動原因如下:
1、報吿期內,公司各項業務符合年初制定的發展規劃,超聲業務平穩增長、內鏡業務保持較高增速,隨着疫情的常態化,國外業務相比上年同期明顯好轉,總體實現公司收入的顯著增長,淨利潤表現較好。2021年,公司收入規模創歷史新高,代表公司“超聲+內鏡”兩條腿走路戰略日臻成熟,公司經營愈加穩健。憑藉在超聲和內鏡領域的技術優勢,公司積極開拓新產品、新領域,產品應用從超聲科、消化內科拓展到外科和呼吸內科,公司多產品戰略初具雛形。
2、報吿期內,計提商譽減值準備對淨利潤的影響預計為1500–3000萬元。
3、公司與子公司上海威爾遜光電儀器有限公司原股東黃新之間由於業績補償事項導致的仲裁,仍處於審理過程中,公司暫無法預計最終結果。
4、報吿期內,非經常性損益對歸屬於母公司淨利潤的影響金額預計為3300萬元,主要為公司取得的政府補助資金、理財產品收益等,上年同期非經常性損益對歸屬於母公司淨利潤的影響金額為4408萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.